The companion animal vaccines market focuses on vaccines developed to protect pets such as dogs and cats from various infectious diseases. These vaccines play a vital role in preventive veterinary care, helping to control diseases like rabies, distemper, and parvovirus. The market is growing steadily due to rising pet ownership, increasing awareness about animal health, and advances in veterinary medicine. Pet humanization trends and the expansion of veterinary services also support demand. North America leads the market, while Asia-Pacific is witnessing rapid growth due to rising pet adoption and improving access to animal healthcare.
According to Fortune Business Insights, the global companion animal vaccines market was valued at USD 5.43 billion in 2024 and is projected to grow from USD 5.67 billion in 2025 to USD 8.71 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.3% during the forecast period. In 2024, North America dominated the market with a 43.46% share.
In June 2024, Merck Animal Health launched its NOBIVAC NXT Rabies portfolio in Canada, including NOBIVAC NXT Feline‑3 Rabies and NOBIVAC NXT Canine‑3 Rabies. This strategic product rollout underscores the company’s leadership in preventive pet healthcare and commitment to expanding vaccine coverage in key regional markets.
The primary growth drivers fueling the expansion of the companion animal vaccines market include: